Stocks Health care FHTX
NASDAQ · Health careFoghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. brought in $36.7M of revenue over the twelve months to June 30, 2026, up 52.0% from a year earlier. It posted a net loss of $64.6M. In fiscal 2025 capital spending exceeded operating cash flow by $86.1M. At June 30, 2026 it held $68.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Foghorn Therapeutics Inc. does
Foghorn Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FHTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $30.9M | -$74.3M | -$1.18 | -$86.1M |
| 2024 | $22.6M | -$86.6M | -$1.58 | -$101.3M |
| 2023 | $34.2M | -$98.4M | -$2.34 | -$119.3M |
| 2022 | $19.2M | -$108.9M | -$2.62 | $192.4M |
| 2021 | $1.3M | -$101.3M | -$2.73 | -$53.6M |
| 2020 | $430K | -$68.8M | -$6.23 | -$47.5M |
Latest SEC filings
What Foghorn Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 24, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
- May 6, 2026Passive stake changed SCHEDULE 13G/A
- April 30, 2026
- April 30, 2026Additional proxy material DEFA14A
Questions about FHTX
What does Foghorn Therapeutics Inc. do?
Foghorn Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FHTX.
Is Foghorn Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $64.6M on revenue of $36.7M.
How much revenue does Foghorn Therapeutics Inc. make?
Over the twelve months to June 30, 2026 Foghorn Therapeutics Inc. reported revenue of $36.7M. That is 52.0% more than a year earlier.
When did Foghorn Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026.
Similar companies
Follow FHTX
Get an email when Foghorn Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow FHTX: get an email when it filesWhere the numbers come from
Financial figures are the values Foghorn Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.